Results 131 to 140 of about 118,238 (222)

The Epidemiology of HIV‐1 Resistance to Two‐Drug Regimens in Multicenter Cohort From Poland—A Cross‐Sectional Study

open access: yesHealth Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims Concerns about antiretroviral therapy failure are growing among people with HIV receiving two‐drug regimens, as these schemes include fewer active agents, while the prevalence of transmitted resistance in HIV‐1 continues to increase.
Andrzej Załęski   +7 more
wiley   +1 more source

Cytopenias With HIV in the Era of Highly Active Antiretroviral Therapy: Are We Winning the Battle?

open access: yesHealth Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aim Cytopenias remain among the most frequent hematologic complications of HIV infection, affecting treatment outcomes and quality of life. The introduction of highly active antiretroviral therapy has markedly reduced their incidence by restoring immune function and suppressing viral replication.
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Therapeutic Gene Editing: DNA Repair Pathways, Emerging Editors, and Clinical Progress

open access: yesiNew Medicine, Volume 2, Issue 1, March 2026.
ABSTRACT The field of gene editing has evolved rapidly over the past decade, progressing from programmable zinc‐finger nucleases (ZFNs) and transcription activator‐like effector nucleases (TALENs) to the widespread adoption of CRISPR‐Cas systems. First‐generation editors catalyzed genome engineering by introducing targeted double‐strand breaks (DSBs ...
Li‐Kuang Tsai   +7 more
wiley   +1 more source

Prevalence of Transmitted HIV Drug Resistance Among Newly Diagnosed Antiretroviral Therapy-Naive Pregnant Women in Lilongwe and Blantyre, Malawi [PDF]

open access: yes, 2017
In 2006, a survey of transmitted human immunodeficiency virus (HIV) drug resistance (TDR) was conducted in Lilongwe, Malawi. The survey followed the World Health Organization method to classify TDR to nucleoside reverse transcriptase inhibitors (NRTIs ...
Banda, Richard   +6 more
core  

Comparative effectiveness of dolutegravir + lamivudine versus three‐drug regimens in Swedish clinical practice: a nationwide study

open access: yesJournal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Abstract Introduction HIV guidelines recommend switching from a three‐drug regimen (3DR) to dolutegravir + lamivudine (DTG+3TC) for eligible individuals. This retrospective national cohort study used Swedish InfCareHIV registry data to evaluate long‐term outcomes of adults with HIV RNA <50 copies/ml who switched to DTG+3TC or a guideline‐recommended ...
Erik Sörstedt   +9 more
wiley   +1 more source

Improved Safety of Nucleic Acid Amplification Technology Combined With Serological Tests for Screening Blood Donors: A Systematic Review and Meta‐Analysis

open access: yesReviews in Medical Virology, Volume 36, Issue 2, March 2026.
ABSTRACT No laboratory test performed to date provides an absolute guarantee for detecting infectious agents. Nucleic acid amplification techniques/tests (NAT) associated with serological tests can increase safety and provide greater diagnostic accuracy for patients. We investigated the added safety of NAT technology combined with serological tests for
Heloise Skiavine Madeira   +14 more
wiley   +1 more source

HIV drug resistance in children and adolescents on NNRTI-based antiretroviral therapy and subsequent virologic response to dolutegravir-based regimens in Ghana

open access: yesAIDS Research and Therapy
HIV drug resistance (HIVDR) was retrospectively characterized among 20 children and adolescents with HIV with virologic failure on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy, and virologic response in those switched to ...
Adwoa K.A Afrane   +11 more
doaj   +1 more source

Structure of HIV reverse transcriptase [PDF]

open access: yesActa Crystallographica Section A Foundations of Crystallography, 1993
J. Wang   +6 more
openaire   +1 more source

Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing

open access: yesSmall, Volume 22, Issue 16, 17 March 2026.
The review highlights nature‐inspired nanocarriers for CRISPR delivery, emphasizing viral vectors, extracellular vesicles, liposomes, and lipid nanoparticles. It discusses their roles in improving specificity, minimizing immunogenicity, and overcoming barriers in genome editing. Recent advancements, challenges, and therapeutic applications are explored,
Elizabeth Maria Clarissa   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy